Efficacy and safety of ASK120067 (limertinib) in patients with locally advanced or metastatic EGFR T790M-mutated non–small cell lung cancer: A multicenter, single-arm, phase IIb study.
Baolan Li(Capital Medical University), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhiyong He(Fujian Medical University), Yanping Hu(Chinese People's Liberation Army), Yueyin Pan(Anhui Provincial Hospital), Hongjun Gao(Chinese PLA General Hospital), Lin Wu(Materials Systems (United States)), Jian Fang(Peking University), Xiang Wang, Kai Li(China Medical University), Jianhua Shi(Shanxi Datong University), Yu Zhang(Nanjing Chest Hospital), Qin Shi(Soochow University), Rui Ma(Liaoning Cancer Hospital & Institute), Yinghua Ji(First Affiliated Hospital of Xinxiang Medical University), Zhijie Pan(Chinese PLA General Hospital), Yunpeng Liu(Shenyang Institute of Automation), Yun Fan(NOAA National Centers for Environmental Prediction), Hongyu Chen(Wrocław University of Environmental and Life Sciences), Tingting Song(Xinjiang Medical University)
Cited by 3
Related Papers
Simultaneous phase and size control of upconversion nanocrystals through lanthanide doping
|Nature|2010|3.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Ultrathin MoS<sub>2</sub> Nanosheets Supported on N‐doped Carbon Nanoboxes with Enhanced Lithium Storage and Electrocatalytic Properties
|Angewandte Chemie International Edition|2015|629